
    
      This was a randomized, observer-blind, multinational, comparator and placebo-controlled
      parallel group, (3:3:1 ratio) study to compare the efficacy and safety of BF-200 ALA with the
      comparator MetvixÂ® (methyl-[5-amino-4-oxopentanoate]) and placebo, for the treatment of AK
      with PDT.
    
  